- Home
- NGD vs PCVX Comparison
NGD vs PCVX Comparison
Compare NGD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGD | PCVX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.1B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NGD | PCVX |
|---|---|---|
| Price | $11.06 | $54.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $11.13 | ★ $97.67 |
| AVG Volume (30 Days) | ★ 25.6M | 1.7M |
| Earning Date | 02-18-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1232.42 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,242,200,000.00 | N/A |
| Revenue This Year | $62.14 | N/A |
| Revenue Next Year | $57.44 | N/A |
| P/E Ratio | $35.23 | ★ N/A |
| Revenue Growth | ★ 44.19 | N/A |
| 52 Week Low | $2.60 | $27.66 |
| 52 Week High | $13.63 | $86.45 |
Technical Indicators
Market Signals| Indicator | NGD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.27 | 55.52 |
| Support Level | $10.33 | $51.34 |
| Resistance Level | $11.68 | $58.00 |
| Average True Range (ATR) | 0.88 | 3.31 |
| MACD | -0.12 | -0.22 |
| Stochastic Oscillator | 44.78 | 42.60 |
Price Performance
Historical ComparisonAbout NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.